We recently compiled a list of the 12 Best NYSE Penny Stocks to Buy According to Analysts. In this article, we are going to take a look at where Nuvation Bio Inc. (NYSE:NUVB) stands against the other NYSE penny stocks.
President Trump’s tariffs on Canada and Mexico went live on March 4, 2025, after a one-month moratorium, prompting retaliatory tariffs from both countries and China. This “game of tariffs” is expected to impact the US economy significantly. Immediately after Trump’s announcement, the S&P 500 fell to a new low (5,732.59) since November last year. Although the index had recouped some losses slightly (to 5,778.15 at the time of writing), the message is clear: Trump has ignited a full-blown trade war, and investors aren’t willing to take any losses.
Legendary investor Warren Buffett commented on this situation, saying the American people will suffer the sharpest pain from the tariffs. “Tariffs are actually, we’ve had a lot of experience with them. They’re an act of war, to some degree. Over time, they are a tax on goods. I mean, the tooth fairy doesn’t pay ’em! And then what? You always have to ask that question in economics. You always say, ‘And then what?’” Buffet told CBS News’ Norah O’Donnell.
READ ALSO: 10 Stocks Targeted by Activist Investors Right Now and 8 Best Value Penny Stocks to Invest in Now.
However, others see this policy as the Trump administration’s strategy to try to renegotiate some of the trade deals the US has with the countries in question. Spencer Ford, CEO and Wealth Advisor with Conservative Financial Solutions believes that this administration wants to win in the eyes of Americans, and if tariffs are the way, so be it. Although he doesn’t hesitate to suggest a better approach:
“The way they’re gonna do that [score better trade deals] is through a strong economy, and you don’t do that through prolonged tariffs because it just makes things more expensive. They’re [tariffs] inflationary. And as we’ve seen, it’s not really good for the investment markets. I think a lot of people are hoping maybe we’ll see what happened from Friday to today with Ukraine where, Yeah. Suddenly there’s a change of heart there.”
Will Trump change heart? Probably. US Commerce Secretary Howard Lutnick recently announced that President Trump will likely announce a deal to cut tariffs on the neighbors. “Both the Canadians and Mexicans were on the phone with me all day today trying to show that they’ll do better on reducing the flow of the synthetic opioid fentanyl into the US,” he told Fox Business Network.
But whatever happens, the damage has already been done. Looking at the NYSE, most companies listed on the exchange have been doing great since Trump’s comeback at the White House. The NYSE Composite Index has been in the green since January 10, 2025. However, this growth was almost wiped off in a single day when the US tariffs were effected, and the target countries announced retaliations.
On the very day the tariffs were effected, the NYSE shed over 2% in value. This index includes a mix of large-cap, mid-cap, and small-cap shares, but the scales tip towards large-cap stocks. This tells you that when the index posts losses, the sell-off affects large-cap stocks more. Granted, small-caps were also affected but the largest impact went to the huge conglomerates that often operate across borders.
The latest data shows that NYSE stocks are recovering—the NYSE has so far climbed 1.33% (as of the close on March 5). A lot of this activity is investors’ optimism about a tariff reprieve across more sectors after Trump gave the big three automakers a one-month reprieve. But whether this will happen is a question no one can answer right now. That means that the possibility of the NYSE stocks taking another dip in the future is real. And the shares whose value is much more at stake are the large-caps, which makes this an opportune time to consider NYSE penny stocks.
Our Methodology
To assemble these companies, we used stock screeners to identify NYSE stocks trading under $5. We filtered the resulting companies and picked 12 stocks based on upside potential (at least 30% as of March 7). Additionally, we have included the hedge fund sentiment around each stock, as of Q4 2024.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points (see more details here).
A close-up of researchers, carefully studying a biopharmaceutical compound in a laboratory.
Nuvation Bio Inc. (NYSE:NUVB)
Price as of March 7: $1.89
Analysts upside potential as of March 7: 455.56%
Number of Hedge Fund Holders In Q4 2024: 34
Nuvation Bio Inc. (NYSE:NUVB) creates therapies and medications to diagnose, treat, and manage cancer. The company’s leading product is taletrectinib, which treats advanced ROS1-positive non-small cell lung cancer (NSCLC). Another product, although it’s yet to reach full development, is NUV-422. This targets high-grade gliomas, including glioblastoma multiforme.
The new year has been active for this company. On March 3, 2025, Nuvation Bio Inc. (NYSE:NUVB) revealed that it had secured a capital injection of $250 million from Sagard Healthcare Partners. This transaction includes $150 million in royalty interest financing, and the rest is a senior term loan. The funds come at the time when the company is working on the commercial launch of taletrectinib in the US, pending FDA approval that may come by mid-2025.
Exactly a month before, the company had initiated an Expanded Access Program (EAP) for taletrectinib in the US. The program allows patients with serious or immediately life-threatening ROS1-positive NSCLC to access the treatment outside of clinical trials. In January 2025, China’s National Medical Products Administration approved taletrectinib for administration to patients inside the Chinese territory. The drug will be marketed as DOVILERON through a partner, Innovent Biologics.
These developments fulfill the promises the management made last year when presenting the Q3 2024 financial results. During that event, the company showed that its financial position was strong (cash, cash equivalents, and marketable securities totaled $549.1 million), and it looks like the fourth quarter will be better. As such, one understands why investors believe that the stock should be trading at 455.56% of the current price, and this is why these shares take the top spot in our list of 12 best NYSE penny stocks to buy, according to analysts.
Overall NUVB ranks 1st on our list of the best NYSE penny stocks to buy according to analysts. While we acknowledge the potential of NUVB as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than NUVB but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock.
READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires.
Disclosure: None. This article is originally published at Insider Monkey.
